MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Quanterix Corporation Operating Income 2011-2026 | QTRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Quanterix Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -126 M | -52.6 M | -46 M | -102 M | -58.6 M | -31.6 M | -41.6 M | -31.6 M | -26 M | -21.7 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.7 M | -126 M | -53.7 M |
Quarterly Operating Income Quanterix Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.3 M | -37.1 M | -26.4 M | - | -11.7 M | -10.9 M | -15.2 M | - | -9.56 M | -9.42 M | - | -36.6 M | -25 M | -18.2 M | - | -15.2 M | -13.7 M | -9.79 M | -9.93 M | 2.28 M | -12.2 M | -11.7 M | -11.5 M | -10.2 M | -10.5 M | -9.36 M | -9.41 M | -7.66 M | -7.31 M | -7.16 M | -7.09 M | -6.39 M | -6.47 M | -6.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.28 M | -37.3 M | -13.6 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
608 M | $ 185.02 | -0.81 % | $ 13.9 B |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 38.94 | -1.37 % | $ 5.8 K | USA |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 12.58 | -0.55 % | $ 1.7 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.61 | 3.18 % | $ 38 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.59 | 1.99 % | $ 134 M |  France |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 63.42 | -1.83 % | $ 93.9 B | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 10.5 | 0.38 % | $ 297 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
9.66 M | $ 25.39 | -1.24 % | $ 215 M | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.8 | -7.2 % | $ 69.4 M | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 16.53 | -7.39 % | $ 388 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 92.76 | -1.87 % | $ 12.5 B | USA |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.06 | 6.19 % | $ 1.25 M | USA |
 |
Butterfly Network
BFLY
|
-74.4 M | $ 5.29 | 8.74 % | $ 1.12 B | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.59 | 6.29 % | $ 175 M | USA |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.04 | - | $ 17.6 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 10.83 | -1.46 % | $ 388 M | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 56.45 | -0.34 % | $ 1.66 B | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 37.91 | -3.88 % | $ 1.18 B | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 65.01 | -0.2 % | $ 3.55 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 88.37 | 0.49 % | $ 3.07 B | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.76 | -0.05 % | $ 123 M | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 79.05 | 1.09 % | $ 46.2 B | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.68 | -2.19 % | $ 7.43 M | USA |
 |
Penumbra
PEN
|
189 M | $ 331.47 | -0.29 % | $ 12.9 B | USA |